ID   JMP-1
AC   CVCL_UJ14
SY   JMP1
DR   ATCC; CRL-3378
DR   Wikidata; Q94331135
RX   PubMed=16497967;
RX   PubMed=29666304;
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC=CRL-3378
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 9,13
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   TH01: 6,9
ST   TPOX: 8,10
ST   vWA: 14,17
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 02-05-24; Version: 6
//
RX   PubMed=16497967; DOI=10.1182/blood-2005-10-4042; PMCID=PMC1895801;
RA   Fu L.-C., Lin-Lee Y.-C., Pham L.V., Tamayo A.T., Yoshimura L.C.,
RA   Ford R.J. Jr.;
RT   "Constitutive NF-kappaB and NFAT activation leads to stimulation of
RT   the BLyS survival pathway in aggressive B-cell lymphomas.";
RL   Blood 107:4540-4548(2006).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//